Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching US$8.85 billion ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen Pharmachem Industries Ltd share price ... data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from ...